RLAY vs TVTX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
RLAY · Relay Therapeutics$18.60 ▲ 9.41%
TVTX · Travere Therapeutic$49.60 ▲ 1.49%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- RLAY +201.5%
- TVTX +44.3%
Head to head
| Metric | RLAY | TVTX |
|---|---|---|
| Price | $18.60 | $49.60 |
| Change today | ▲ 9.41% | ▲ 1.49% |
| Market cap | $4.11B | $4.76B |
| Return, 3 months | -6.7% | -18.5% |
| Return, year to date | +119.9% | +29.8% |
| Return, 1 year | +207.4% | +53.4% |
| P/E (TTM) | – | – |
| P/B | 5.0 | 211.1 |
| P/E percentile vs own 5y | 6th | 11th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -48.3% | +48.2% |
| Net profit growth (YoY) | -18.9% | -172.8% |
| Gross margin | – | 97.6% |
| Operating margin | -2,999.4% | -6.8% |
| Net margin | -2,763.6% | -7.4% |
| Return on equity | -36.8% | -151.8% |
| Analyst target vs. price | +45.2% | +53.1% |
| Analyst buy share | 100% | 92% |
| RSI (14) | 53 | 40 |
| 30-day volatility | 62.7% | 46.0% |
| Max drawdown, 1 year | -28.2% | -33.5% |
| Trend read | Strong uptrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TVTX is the largest of the group by market value.
- RLAY has returned the most over the past year.
- TVTX is growing revenue fastest.
- TVTX keeps the most profit per dollar of sales.
- TVTX has been the calmest stock over the last 30 days.